{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T14:34:48Z","timestamp":1771684488453,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,18]]},"DOI":"10.7759\/cureus.9831","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T11:49:49Z","timestamp":1597751389000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case of Seronegative ANA Hydralazine-Induced Lupus Presenting With Pericardial Effusion and Pleural Effusion"],"prefix":"10.7759","author":[{"given":"Karim O","family":"Elkholy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abishek","family":"Chakraborti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Drug-induced lupus","volume":"100","author":"Rich MW","year":"1996","unstructured":"Rich MW. Drug-induced lupus. Postgraduate Medicine. 1996, 100:299-308. https:\/\/doi.org\/10.3810\/pgm.1996.09.83","journal-title":"Postgraduate Medicine"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor A","year":"2004","unstructured":"Taylor A, Ziesche S, Yancy C, et al.. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004, 351:2049-2057.","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/01.smj.0000197121.12352.19","article-title":"Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure","volume":"99","author":"Finks SW","year":"2006","unstructured":"Finks SW, Finks AL, Self TH. Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure. South Med J. 2006, 99:18-22. 10.1097\/01.smj.0000197121.12352.19","journal-title":"South Med J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1954.73690350001010","article-title":"Lupus erythematosus-like syndrome complicating hydralazine (apresoline) therapy","volume":"155","author":"Reinhardt DJ","year":"1954","unstructured":"Reinhardt DJ, Waldron JM. Lupus erythematosus-like syndrome complicating hydralazine (apresoline) therapy. J Am Med Assoc. 1954, 155:1491-1492. 10.1001\/jama.1954.73690350001010","journal-title":"J Am Med Assoc"},{"key":"ref5","article-title":"The lupus syndrome induced by hydralazine: a common complication with low dose treatment","volume":"289","author":"Cameron HA","year":"1984","unstructured":"Cameron HA, Ramsay LE . The lupus syndrome induced by hydralazine: a common complication with low dose treatment. BMJ. 1984, 289:410-412. https:\/\/doi.org\/10.1136\/bmj.289.6442.410","journal-title":"BMJ"},{"key":"ref6","article-title":"Clinical pharmacokinetics of vasodilators","volume":"34","author":"Kirsten R","year":"1998","unstructured":"Kirsten R, Nelson K, Kirsten D, et al.. Clinical pharmacokinetics of vasodilators. Clin Pharmacokinet. 1998, 34:457-482. https:\/\/doi.org\/10.2165\/00003088-199834060-00003","journal-title":"Clin Pharmacokinet"},{"key":"ref7","article-title":"Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling","volume":"48","author":"Denge C","year":"2003","unstructured":"Denge C, Lu Q, Zhang Z, et al.. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum. 2003, 48:746-756. https:\/\/doi.org\/10.1002\/art.10833","journal-title":"Arthritis Rheum"},{"key":"ref8","article-title":"Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis","volume":"54","author":"Perry","year":"1973","unstructured":"Perry, HM. Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med. 1973, 54:58-72. https:\/\/doi.org\/10.1016\/0002-9343(73)90084-3","journal-title":"Am J Med"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2004.12.025","article-title":"Drug-induced lupus","volume":"209","author":"Rubin","year":"2005","unstructured":"Rubin, RL. Drug-induced lupus. Toxicology. 2005, 209:135-147.","journal-title":"Toxicology"},{"key":"ref10","article-title":"Hydralazine induced lupus syndrome presenting with recurrent pericardial effusion and a negative antinuclear antibody","author":"Iyer P","year":"2017","unstructured":"Iyer P, Dirweesh A, Zijoo R. Hydralazine induced lupus syndrome presenting with recurrent pericardial effusion and a negative antinuclear antibody. Case Rep Rheumatol. 2017, 1-3.","journal-title":"Case Rep Rheumatol"},{"key":"ref11","article-title":"ANA-negative hydralazine-induced pericardial effusion","author":"Zeitjian V","year":"2017","unstructured":"Zeitjian V, Mehdizadeh A. ANA-negative hydralazine-induced pericardial effusion. Case Rep Med. 2017, 1-3. https:\/\/doi.org\/10.1155\/2017\/3521541","journal-title":"Case Rep Med"},{"key":"ref12","article-title":"Hydralazine induced pericardial effusion","volume":"75","author":"Tahir M","year":"2020","unstructured":"Tahir M, Rai D, Tahir Z, Roy S, Baibhav B. Hydralazine induced pericardial effusion. J Am Coll Cardiol. 2020, 75:3362. https:\/\/doi.org\/10.1016\/s0735-1097(20)33989-9","journal-title":"J Am Coll Cardiol"},{"key":"ref13","article-title":"Hydralazine-induced lupus syndrome presenting with large pericardial effusion","volume":"107","author":"Chamsi-Pasha M","year":"2013","unstructured":"Chamsi-Pasha M, Bassiouny M, Kim E. Hydralazine-induced lupus syndrome presenting with large pericardial effusion. QJM. 2013, 107:305-307. https:\/\/doi.org\/10.1093\/qjmed\/hct223","journal-title":"QJM"},{"key":"ref14","article-title":"Drug induced lupus presenting as isolated pleural effusion","volume":"148","author":"Ajakumar Menon A","year":"2015","unstructured":"Ajakumar Menon A, Kirshenbaum D, Burke G. Drug induced lupus presenting as isolated pleural effusion. Chest. 2015, 148:884A. https:\/\/doi.org\/10.1378\/chest.2236839","journal-title":"Chest"},{"key":"ref15","article-title":"Antinuclear antibody-negative, drug- induced lupus caused by lisinopril","volume":"94","author":"Carter J","year":"2001","unstructured":"Carter J, Valeriano-Marcet J, Kanik K, et al.. Antinuclear antibody-negative, drug- induced lupus caused by lisinopril. South Med J. 2001, 94:1122-1123. https:\/\/doi.org\/10.1097\/00007611-200111000-00017","journal-title":"South Med J"},{"key":"ref16","article-title":"Antinuclear antibody-negative lupus? An ominous presentation of hydralazine-induced lupus syndrome","volume":"5","author":"Solomon-Tsegaye T","year":"2018","unstructured":"Solomon-Tsegaye T, Treadwell E, Obi R, Pitzalis, M. Antinuclear antibody-negative lupus? An ominous presentation of hydralazine-induced lupus syndrome. Eur J Rheumatol. 2018, 5:272-274. https:\/\/doi.org\/10.5152\/eurjrheum.2018.18040","journal-title":"Eur J Rheumatol"},{"key":"ref17","article-title":"Drug-Induced Lupus Erythematosus. [Updated 2020 Jul 4]","author":"Solhjoo M","year":"2020","unstructured":"Solhjoo M, Bansal P, Goyal A, et al.. Drug-Induced Lupus Erythematosus. [Updated 2020 Jul 4]. StatPearls Publishing, Treasure Island; 2020."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/22982-a-case-of-seronegative-ana-hydralazine-induced-lupus-presenting-with-pericardial-effusion-and-pleural-effusion","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:25:02Z","timestamp":1707506702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/22982-a-case-of-seronegative-ana-hydralazine-induced-lupus-presenting-with-pericardial-effusion-and-pleural-effusion"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.9831","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,18]]}}}